 HOLON, Israel, April 29, 2021 PRNewswire -- Compugen Ltd. Nasdaq: CGEN, a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that it will present updates on its ongoing Phase 1 clinical trial evaluating COM701, a first-in-class therapeutic antibody targeting PVRIG, in an oral presentation at the American Society of Clinical Oncology ASCO 2021 Annual Meeting, being held virtually on June 4-8, 2021. 